Posted in International

U.S. pharmaceutical company Modena to supply Taiwan with 5 million doses of vaccines for mid-year delivery

 2021年2月10日

U.S. pharmaceutical company Moderna announced Feb. 9 that it has signed vaccine supply agreements with the governments of Taiwan and Colombia to provide 5 million and 10 million doses of the 2019 coronavirus disease (CVD) vaccine, respectively.

Modena issued a statement noting that vaccine deliveries under the agreement will begin in mid-2021.

The statement said that Modena’s COVID-19 (Chinese Communist Virus) vaccine has not yet been approved for use in Taiwan and Colombia, but they will work with the drug authorities in both countries with a view to approving the vaccine before it is delivered and dispatched.

Stephane Bancel, CEO of Modena, said, “We are grateful to the governments of Taiwan and Colombia for working with us to bring the Modena vaccine to both countries. Both governments acted quickly to finalize agreements in the face of the pandemic, and we appreciate the collaborative support of both governments.”

Countries currently approved for the Modena vaccine include Canada, Israel, the European Union, the United Kingdom, Switzerland, and Singapore, and Modena has also applied to the World health Organization (WHO), pending approval.

Modena’s COVID-19 vaccine is a so-called messaging ribonucleic acid (mRNA) vaccine, in which laboratory-made mRNA is injected into the human body to teach the body to recognize the spine protein of a new coronavirus (CCLV) and produce neutralizing antibodies to block the virus before it causes infection. is also an mRNA vaccine.

The Washington Post pointed out that the Modena vaccine released the results of the phase 3 trial on Nov. 16 last year, claiming 95% protection, and the U.S. Food and Drug Administration (FDA) approved it for emergency use on Dec. 18 last year for people over 18 years old.

Reuters reported that Taiwan said in late December last year that it had reached an agreement with various parties to purchase nearly 20 million doses of the vaccine, including 10 million doses of the vaccine from the British pharmaceutical company AstraZeneca/Oxford University.